login
  Password reminder
NeuroNews
Contact the editor Visit NeuroNews Twitter feed Visit NeuroNews Facebook page
 

Preliminary results of laser ablation promising for inoperable brain tumours and epilepsy


Friday, 30 Aug 2013 15:05
Laser catheter insertion
Laser catheter insertion

“The results of laser ablation to treat inoperable brain tumours, epilepsy and refractory cancer pain are very exciting,” Shabbar F Danish, director, Stereotactic and Functional Neurosurgery and assistant professor at Rutgers-Robert Wood Johnson Medical School and Robert Wood Johnson University Hospital, New Brunswick, USA, told NeuroNews.


What are the preliminary results of laser ablation performed on patients at Robert Wood Johnson?

We have performed over 100 laser procedures to date. The preliminary results are very exciting as we are able to achieve outcomes similar to open procedures without the side-effects of an open procedure in many types of cases.

 

What is the evidence in the literature for use of laser ablation for epilepsy?

Ablation techniques have been used to treat brain tumours for many years, starting in the late 1980s. The use for epilepsy is fairly new, being introduced in 2010. We are just starting to see this data in the literature for epilepsy. This year will mark the beginning of the first national multicentre trial to understand the efficacy of laser therapy in the treatment of temporal lobe epilepsy.

Alternative treatments for brain tumour patients include chemotherapies, radiation therapies, and open surgery. The traditional treatment for refractory epilepsy involves an open craniotomy. This procedure aims to achieve the same outcome without having the patients undergo an open operation.

What improvements do patients see after the procedure?

It depends on the type of disease being treated. For patients with brain tumours, we are able to get the tumours to stop growing. For epilepsy patients, we are able to cure their seizures and patients become seizure free. There are some tumours that we have been able to cure, and others that require a repeat treatment to keep them under control. Tumour growth is monitored with close imaging, and recurrence is objectified via analysis by a multidisciplinary neuro-oncology board. Outcomes for epilepsy patients are monitored using the Engel classification system. Patients treated for refractory pain syndromes are monitored using the brief pain inventory (BPI)-short form.

 

What type of patient is the suitable candidate for laser ablation?

Patients diagnosed with any type of brain tumour who have been told they do not have other options, patients with epilepsy that has not responded to medications, and patients with cancer-related pain may be candidates for laser ablation. In addition, patients who have had CyberKnife or gamma knife surgery for a brain tumour that then grows back are very good candidates for this therapy.

 

What are the complications associated with laser ablation?

Complications associated with the procedure include a 1% risk of haemorrhage or stroke. There is a 2–5% chance that the laser is not placed in an optimal position and there is a risk that the tumour or epilepsy focus is not completely ablated. In the latter case, the procedure can be repeated.

 

What is your message to other neurointerventionists?

I think that it is important to consider a minimally invasive option when it exists. The open or more risky alternative is always an option, but as we have learned from other specialties in medicine, if we can achieve the same outcomes with a minimally invasive procedure, why would we not take that approach?

 

Do you involve other specialties in case selection?

We approach all patients through a multidisciplinary board and when this approach is not appropriate will recommend alternative strategies. We believe that all patients and physicians should be educated about all the options that exist, especially if one is available that affords the patients less morbidity from the procedure.




Add New Comment

Related Items


Most popular


Groundbreaking studies find that neurointerventional surgery reduces stroke mortality
Wednesday, 11 Feb 2015
Two new clinical trials on the treatment of stroke (ESCAPE and EXTEND IA) demonstrate that neurointerventional surgery significantly increases the number of patients who are able to live ... Groundbreaking studies find that neurointerventional surgery reduces stroke mortality

FDA approves Pipeline Flex embolisation device
Thursday, 05 Feb 2015
Designed to divert blood flow away from an aneurysm, the Pipeline Flex embolisation device (Medtronic) features a braided cylindrical mesh tube that is implanted across the base or neck of the ... FDA approves Pipeline Flex embolisation device

New programme helps gauge blood flow during flow diverter treatment of aneurysms
Tuesday, 03 Feb 2015
A new computer programme allows interventionalists to assess blood flow in real-time while they are using flow-diverter devices to treat intracranial aneurysms, suggests a pilot study being presented ... New programme helps gauge blood flow during flow diverter treatment of aneurysms

Features


Total small-vessel disease score: a new and pragmatic way to assess the full impact of small-vessel disease on the brain
Thursday, 26 Feb 2015
The score provides a more complete overall view of the impact of small-vessel disease on the brain than do the individual MRI features separately. It is a simple and pragmatic visual quantification ... Total small-vessel disease score: a new and pragmatic way to assess the full impact of small-vessel disease on the brain

Focus on: Neuromodulation
Monday, 09 Feb 2015
Over the past decade, neuromodulation has grown into a wide and varied field with approvals for additional applications increasing every year. NeuroNews now speaks to four thought-leaders in the ... Focus on: Neuromodulation

Profiles


Joseph Broderick
Wednesday, 07 Jan 2015
Joseph Broderick speaks to NeuroNews about the future of neurology and his research, in particular, ... Joseph Broderick

Vladimír Beneš Jr
Tuesday, 30 Sep 2014
Vladimír Beneš Jr is professor and chair at the First Medical School, Charles University, P... Vladimír Beneš Jr

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions